Domača stranFTRE • NASDAQ
add
Fortrea Holdings Inc
Prejšnji trg. dan.
20,69 $
Dnevni razpon
20,87 $ - 21,60 $
Letni razpon
16,53 $ - 41,02 $
Tržna kapitalizacija
1,84 mrd. USD
Povprečni obseg
1,33 mio.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(USD) | sep. 2024info | Sprememba L/L |
---|---|---|
Prihodek | 674,90 mio. | −5,45 % |
Stroški poslovanja | 157,50 mio. | 21,53 % |
Čisti dohodek | −27,90 mio. | −99,29 % |
Čista dobičkovnost prihodkov | −4,13 | −110,71 % |
Earnings per share | 0,23 | −4,17 % |
EBITDA | 12,00 mio. | −72,22 % |
Efektivna davčna stopnja | 48,32 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
(USD) | sep. 2024info | Sprememba L/L |
---|---|---|
Denar. in kratkor. naložbe | 105,30 mio. | −4,01 % |
Skupna sredstva | 3,66 mrd. | −15,13 % |
Skupne obveznosti | 2,15 mrd. | −18,01 % |
Celoten lastniški kapital | 1,51 mrd. | — |
Shares outstanding | 89,70 mio. | — |
Razmerje P/B | 1,23 | — |
Donosnost sredstev | −0,64 % | — |
Donosnost kapitala | −0,85 % | — |
Denarni tok
Neto sprememba denarnih sredstev
(USD) | sep. 2024info | Sprememba L/L |
---|---|---|
Čisti dohodek | −27,90 mio. | −99,29 % |
Denar iz dejavnosti | −2,40 mio. | −226,32 % |
Denar iz naložb | −8,10 mio. | −400,00 % |
Denar iz financiranja | −14,00 mio. | −81,82 % |
Neto sprememba denarnih sredstev | −20,90 mio. | −309,80 % |
Prost denarni tok | −19,35 mio. | −269,37 % |
Vizitka
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Generalni direktor
Datum ustanovitve
apr. 1996
Spletno mesto
Zaposleni
15.500